DCT & HYBRID CLINICAL TRIALS

SAMD for Pharma

SAMD for Pharma

Accelerate recruitment and ‘first patient in’ time

Streamlined user journeys help accelerate time to “first patient in” and get your trial up and running with minimal fuss.

Fully-integrated screening and consent enable faster set-up and enrollment. Our DeTAP atrial fibrillation trial recruited 94% of participants in less than two weeks and maintained an 86% retention rate.

Powering digital-first clinical research

eConsent

eCOA/ePRO

Telemedecine

Connected devices

Seamless set up and go

Maximise participant sign-ups and minimise dropouts with an uninterrupted screening-to-consent process. Invite participants by email directly from the platform and get them up and running quickly with our easy-to-use, step-by-step onboarding module featuring efficient electronic ID verification.

Comprehensive support for multiple market recruitment strategies

The Huma platform is ready to deploy immediately in 80+ countries across the US, Europe, China, Middle East, Southeast Asia, and more. We’re device and cloud-agnostic for the widest possible global deployment flexibility.

We have the ability to recruit participants globally via sites, central participant hubs and recruitment marketing campaigns.

Regulatory, safety and compliance

EU MDR 2017/745
Class IIb certified

MHRA registered Medical Device Class IIb

21CFR820 US FDA Class II

US Food and Drug Administration Medical Device 510k # K230214

ISO certifications

ISO 13485: 2016 certified (Medical Devices: Quality Management Systems)


ISO 27001: 2022 certified

Data protection / infosec

Committed to GDPR compliance


NHS Registration on Data Security and Protection Toolkit


CyberEssentials / CyberEssentials Plus

Integrated support and expert team

Huma’s experienced team is on-hand to ensure your therapeutic trial is set up to your exact requirements. Our fully-regulated platform can be deployed across multiple countries and offers reliability and a high degree of user acceptance at scale.

Request a meeting

Huma is committed to respecting your privacy, and we’ll only use your personal details to provide information you have selected you’re interested in. Review our Privacy Policy for further information.

We’d love to send you our monthly newsletter about our latest work, research and events by email. We’ll always treat your personal details with the utmost care and will never sell them to other companies for marketing purposes.

Sources

Long Title

  1. Sarraju, A., Seninger, C., Parameswaran, V. et al. Pandemic-proof recruitment and engagement in a fully decentralized trial in atrial fibrillation patients (DeTAP). npj Digit. Med. 5, 80 (2022). https://doi.org/10.1038/s41746-022-00622-10

Long Title